Arvinas (ARVN) Stock Price, News & Analysis

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

16 Wall Street research analysts have issued twelve-month price objectives for Arvinas' stock. Their ARVN share price targets range from $20.00 to $90.00. On average, they expect the company's stock price to reach $59.73 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $41.16 at the beginning of 2024. Since then, ARVN stock has decreased by 17.6% and is now trading at $33.90.
View the best growth stocks for 2024 here.

Arvinas saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the short-interest ratio is presently 11.7 days.
View Arvinas' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by $1.38. The firm had revenue of ($43.10) million for the quarter, compared to the consensus estimate of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. During the same period in the previous year, the firm posted ($1.56) EPS.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO).iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (0.30%), Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.02%) and Cullinan Associates Inc. (0.01%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.